How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response
An HIV Research for Prevention // Virtual Conference Satellite – 3 February 2021
An HIV Research for Prevention // Virtual Conference Satellite – 3 February 2021
What HIV vaccine R&D did for COVID-19
A Global HIV Vaccine Enterprise sponsored satellite at the IAS – Research for Prevention conference (R4P Virtual). Wednesday 3 February 2021.
Much about the COVID-19 pandemic has been unprecedented including the global COVID-19 vaccine response. COVID-19 vaccine development has taken place at a speed that was previously thought to be impossible. We have seen multiple vaccines licensed for emergency use with some being rolled out within a year of sequencing the SARS-CoV-2 virus.
The breadth and scope of the vaccine research has also been remarkable, with more than 50 vaccine candidates in clinical trials to date. About half of these are based on next generation platforms – such as viral vector and nucleic acid technologies. And because of this effort, we now have RNA vaccines approved for emergency use for the first time.
As much as $90B US Dollars has been invested into COVID-19 vaccine R&D. Countries and coalitions have funded advance purchases of as many as 7.2 billion doses from a dozen or so developers.
Of course, much of this record-breaking success can be attributed to the sense of need and urgency triggered by the first global pandemic in a 100 years. But even in this context, COVID-19 vaccine development would have been significantly slower without the significant and unique contribution of the HIV vaccine research field.
The Enterprise set out to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.
In this presentation at the HIV R4P // Virtual Conference, Dr. Roger Tatoud, presents the finding of this investigation. Information gathering included interviews with over a dozen leaders from the HIV vaccine field (many of whom are contributing to the COVID-19 vaccine effort), as well as secondary research and analyses. The interviews and other research were led by our colleagues at Shift Health, a strategy firm with a long history of supporting the HIV vaccine field.
This work is still in progress and today’s presentation will describe some of our findings to date as we continue to reflect on this topic.
Established in 2003, the Global HIV Vaccine Enterprise (the Enterprise) became a programme of IAS – the International AIDS Society – in 2018. The Enterprise unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
IAS – the International AIDS Society
Avenue de France 23
CH-1202 Geneva
Switzerland
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy policy